Matthew T. Warkentin

698 total citations
32 papers, 283 citations indexed

About

Matthew T. Warkentin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Matthew T. Warkentin has authored 32 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Matthew T. Warkentin's work include Lung Cancer Diagnosis and Treatment (12 papers), Global Cancer Incidence and Screening (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Matthew T. Warkentin is often cited by papers focused on Lung Cancer Diagnosis and Treatment (12 papers), Global Cancer Incidence and Screening (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Matthew T. Warkentin collaborates with scholars based in Canada, United States and United Kingdom. Matthew T. Warkentin's co-authors include Darren R. Brenner, Rayjean J. Hung, Stephen Lam, Daniel Y.C. Heng, Chun Loo Gan, Richard M. Lee‐Ying, Safiya Karim, Marianne D. Sadar, S. Larry Goldenberg and John M. Crook and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and JNCI Journal of the National Cancer Institute.

In The Last Decade

Matthew T. Warkentin

24 papers receiving 274 citations

Peers

Countries citing papers authored by Matthew T. Warkentin

Since Specialization

Citations

This map shows the geographic impact of Matthew T. Warkentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew T. Warkentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew T. Warkentin more than expected).

Fields of papers citing papers by Matthew T. Warkentin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew T. Warkentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew T. Warkentin. The network helps show where Matthew T. Warkentin may publish in the future.

Co-authorship network of co-authors of Matthew T. Warkentin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew T. Warkentin. A scholar is included among the top collaborators of Matthew T. Warkentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew T. Warkentin. Matthew T. Warkentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increasing Cervical Cancer Rates Among Women Age 35-54 Years in Canada: Age-Specific Cervical Cancer Incidence Trends in Canada, 1992-2022 2025 ·PubMed ·Ioana Nicolau, Matthew T. Warkentin, (unknown), Corinne Doll, Heather E. Bryant, Darren R. Brenner	0
2	MA05.06 Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts 2025 ·Journal of Thoracic Oncology ·Elham Khodayari Moez, (unknown), Matthew T. Warkentin, Brenda Diergaarde, David O. Wilson, Jian‐Min Yuan, Stephen Lam, John K. Field, Michaela Davies, Geoffrey Liu, Luis M. Montuenga, Yonathan Brhane, (unknown), Christopher I. Amos, Hilary A. Robbins, (unknown), Rayjean J. Hung	0
3	Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050? 2025 ·Cancer Control ·(unknown), Yibing Ruan, (unknown), (unknown), (unknown), Matthew T. Warkentin, Andrew J. Coldman, Rochelle Garner, Hawre Jalal, Darren R. Brenner	0
4	Age-specific colorectal cancer incidence trends in Canada, 1971–2021 2024 ·Cancer Epidemiology ·Emily Heer, Yibing Ruan, Matthew T. Warkentin, Robert J. Hilsden, Linda Rabeneck, Dylan E. O’Sullivan, Darren R. Brenner	1
5	Progress in site-specific cancer mortality in Canada over the last 70 years 2024 ·Scientific Reports ·Matthew T. Warkentin, Yibing Ruan, Larry F. Ellison, Jean‐Michel Billette, Alain Demers, Fei‐Fei Liu, Darren R. Brenner	7
6	Risk of Developing a Subsequent Primary Cancer among Adult Cancer Survivors 2024 ·Cancer Epidemiology Biomarkers & Prevention ·Matthew T. Warkentin, Winson Y. Cheung, Darren R. Brenner, Dylan E. O’Sullivan	1
7	Examining breast cancer screening recommendations in Canada: The projected resource impact of screening among women aged 40–49 2024 ·Journal of Medical Screening ·(unknown), Yibing Ruan, (unknown), Matthew T. Warkentin, Oğuzhan Alagöz, Andrew J. Coldman, Darren R. Brenner	0
8	Brief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening 2024 ·Journal of Thoracic Oncology ·Matthew T. Warkentin, Martin C. Tammemägi, Erik Vakil, Eric L.R. Bédard, Winson Y. Cheung, Darren R. Brenner, Alain Tremblay	0
9	Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches 2024 ·Thorax ·Matthew T. Warkentin, (unknown), Stephen Lam, Geoffrey Liu, Brenda Diergaarde, Jian‐Min Yuan, David O. Wilson, Sukhinder Atkar-Khattra, (unknown), Yonathan Brhane, Elham Khodayari Moez, (unknown), Martin C. Tammemägi, Kieran R. Campbell, Rayjean J. Hung	30
10	MA02.11 Validation of the Sybil Deep Learning Lung Cancer Risk Prediction Model in Three Independent Screening Studies 2024 ·Journal of Thoracic Oncology ·(unknown), (unknown), Matthew T. Warkentin, (unknown), Brenda Diergaarde, Jian‐Min Yuan, David O. Wilson, (unknown), R Myers, R. J. Hung	2
11	Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations 2024 ·Annals of the American Thoracic Society ·(unknown), Matthew T. Warkentin, Elham Khodayari Moez, Yonathan Brhane, Geoffrey Liu, Rayjean J. Hung	2
12	1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC) 2023 ·Annals of Oncology ·(unknown), Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, (unknown), J. Connor Wells, Chris Labaki, Bradley A. McGregor, (unknown), Luís Meza, Sumanta K. Pal, Benoit Beuselinck, Rana R. McKay, Bernadett Szabados, Thomas Powles, Takeshi Yuasa, Leopold Ludwig, Toni K. Choueiri, (unknown)	2
13	Circulating proteome for pulmonary nodule malignancy 2023 ·JNCI Journal of the National Cancer Institute ·Elham Khodayari Moez, Matthew T. Warkentin, Yonathan Brhane, Stephen Lam, John K. Field, Geoffrey Liu, Javier J. Zulueta, Karmele Valencia, (unknown), (unknown), Sukhinder Atkar-Khattra, Michael P.A. Davies, (unknown), (unknown), Luis M. Montuenga, Christopher I. Amos, Hilary A. Robbins, Mattias Johansson, Rayjean J. Hung	10
14	Progress in cancer control leads to a substantial number of cancer deaths avoided in Canada 2023 ·JNCI Cancer Spectrum ·Matthew T. Warkentin, Yibing Ruan, Larry F. Ellison, Jean‐Michel Billette, Alain Demers, Fei‐Fei Liu, Darren R. Brenner	2
15	The association between neighborhood‐level income and cancer stage at diagnosis and survival in Alberta 2023 ·Cancer ·Yibing Ruan, Emily Heer, Matthew T. Warkentin, Tamer N. Jarada, Dylan E. O’Sullivan, Desirée Hao, Doreen A. Ezeife, Winson Y. Cheung, Darren R. Brenner	3
16	Probability of lung cancer in a population excluded from screening due to low PLCOM2012 risk 2023 ·Cancer Epidemiology ·Paul MacEachern, Matthew T. Warkentin, Darren R. Brenner, Eric L.R. Bédard, Alain Tremblay	1
17	Lung Cancer Absolute Risk Models for Mortality in an Asian Population using the China Kadoorie Biobank 2022 ·JNCI Journal of the National Cancer Institute ·Matthew T. Warkentin, Martin C. Tammemägi, Osvaldo Espin‐Garcia, Sanjeev Budhathoki, Geoffrey Liu, Rayjean J. Hung	7
18	Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis 2022 ·European Urology Open Science ·(unknown), Matthew T. Warkentin, Chun Loo Gan, Safiya Karim, Daniel Y.C. Heng, Darren R. Brenner, Richard M. Lee‐Ying	53
19	Determinants of impaired lung function and lung cancer prediction among never-smokers in the UK Biobank cohort 2019 ·EBioMedicine ·Matthew T. Warkentin, Stephen Lam, Rayjean J. Hung	25
20	The association between recreational physical activity, sedentary time, and colorectal polyps in a population screened for colorectal cancer 2018 ·Cancer Epidemiology ·Darren R. Brenner, Eileen Shaw, (unknown), Matthew T. Warkentin, Nigel T. Brockton, S. Elizabeth McGregor, Susanna Town, Robert J. Hilsden	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact